Press release
Hereditary Angioedema Therapeutics Market: Key Drivers, Trends, Growth, Outlook 2024-2033
Hereditary Angioedema Therapeutics Market
The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $13.47 billion in 2028 at a compound annual growth rate (CAGR) of 18.8%. The growth in the forecast period can be attributed to advancements in targeted therapies, global market expansion, gene therapy developments, personalized medicine trends, collaboration in research and treatment.. Major trends in the forecast period include global access initiatives, health economic outcomes research, early intervention strategies, pediatric hae therapeutics..
Market Overview -
Hereditary angioedema (HAE) therapeutics refers to therapy for an autosomal dominant condition brought on by a deficiency in or malfunction of the C1-inhibitor protein. Hereditary angioedema symptoms include angioedema-related upper airway, cutaneous, and, or gastrointestinal complaints.
Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp
Surging Prevalence Of Hereditary Angioedema Ignites Growth In The Market
The rising prevalence of hereditary angioedema is expected to propel the growth of the hereditary angioedema market going forward. Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling of the skin and mucous membranes. The swelling is caused by excess fluid build-up (EDEMA) and can occur anywhere in the body, including the hands and feet, face, intestines, and airways. For Instance, in June 2022, according to Rare Disease Advisor, an online resource company that provides health care professionals, globally, 1 in every 50,000 persons suffer from hereditary angioedema with prevalence estimates ranging from 1:10,000 to 1:150,000. HAE episodes cause 15,000 to 30,000 emergency room visits each year in the US. 5.8% of cases of HAE had an average time to diagnosis of 0 to 6 months, whereas 5.8% had an average time to diagnosis of over 10 years. Therefore, the rising prevalence of hereditary angioedema is driving the growth of the hereditary angioedema market.
Competitive Landscape -
Major companies operating in the hereditary angioedema therapeutics market report are Shire plc, Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.
Innovative Therapeutic Advancements Shape The Landscape Of Hereditary Angioedema Market
Product innovations are a key trend gaining popularity in the hereditary angioedema therapeutics market. Major companies operating in the hereditary angioedema therapeutics market are developing innovative products such as ligand-conjugated (LICA) investigational antisense medicine and gene therapy to sustain their position in the market. For Instance, in March 2023, Intellia Therapeutics, a US-based clinical-stage biotechnology company, launched an Investigational New Drug (IND) NTLA-2002, which was approved by the United States Food and Drug Administration for the treatment of hereditary angioedema. This enables the company's ongoing Phase 1/2 trial to include the US in the worldwide Phase 2 part. After a single dose of therapy, the inactivation of the target gene, kallikrein B1 (KLKB1), will permanently lower plasma kallikrein protein activity and prevent HAE attacks. NTLA-2002 is a candidate for in vivo genome editing.
Browse Full Report @
https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report
Key Segments -
The hereditary angioedema therapeutics market covered in this report is segmented -
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand
Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics
"Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "
"Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.
Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps"
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hereditary Angioedema Therapeutics Market: Key Drivers, Trends, Growth, Outlook 2024-2033 here
News-ID: 3478453 • Views: …
More Releases from The Business research company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Hereditary
Unraveling Hereditary Cancer With The Rising Demand For Hereditary Cancer Testin …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Hereditary Cancer Testing Industry Market Size Be by 2025?
The market encompassing hereditary cancer testing has exhibited robust expansion throughout the recent past, projecting an increase from its value of $4.32 billion in 2024 to reach $4.75 billion for the subsequent year, reflecting a consistent annual…
Leber Hereditary Optic Neuropathy Treatment Market
Introduction
Leber Hereditary Optic Neuropathy (LHON) is a genetic condition that leads to severe vision loss, primarily affecting young adults. This disorder is caused by mutations in mitochondrial DNA, which impairs the function of retinal ganglion cells. As awareness of LHON has grown, so too has the focus on its treatment options. The LHON treatment market is evolving rapidly, driven by advancements in genetic therapies, pharmaceuticals, and supportive care strategies. This…
Hereditary Hemochromatosis Market - Redefining Care, Inspiring Hope: Hereditary …
Newark, New Castle, USA: The "Hereditary Hemochromatosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Hereditary Hemochromatosis Market: https://www.growthplusreports.com/report/hereditary-hemochromatosis-market/8793
This latest report researches the industry structure, sales, revenue,…
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.
Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor.
Read more about Hereditary…
